JPH09501927A - 金属錯体を含んで成る医薬組成物 - Google Patents

金属錯体を含んで成る医薬組成物

Info

Publication number
JPH09501927A
JPH09501927A JP7507412A JP50741295A JPH09501927A JP H09501927 A JPH09501927 A JP H09501927A JP 7507412 A JP7507412 A JP 7507412A JP 50741295 A JP50741295 A JP 50741295A JP H09501927 A JPH09501927 A JP H09501927A
Authority
JP
Japan
Prior art keywords
formula
complex
levels
disease
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP7507412A
Other languages
English (en)
Japanese (ja)
Inventor
ジェフリー アブラムズ，マイケル
ポール フリッカー，サイモン
アンソニー マーラー，バリー
ジョン ボーハン，オウェン
Original Assignee
ジョンソン マッセイ パブリック リミティド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジョンソン マッセイ パブリック リミティド カンパニー filed Critical ジョンソン マッセイ パブリック リミティド カンパニー
Publication of JPH09501927A publication Critical patent/JPH09501927A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP7507412A 1993-08-25 1994-08-19 金属錯体を含んで成る医薬組成物 Ceased JPH09501927A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939317686A GB9317686D0 (en) 1993-08-25 1993-08-25 Pharmaceutical compositions
GB9317686.5 1993-08-25
PCT/GB1994/001817 WO1995005814A1 (en) 1993-08-25 1994-08-19 Pharmaceutical compositions comprising metal complexes

Publications (1)

Publication Number Publication Date
JPH09501927A true JPH09501927A (ja) 1997-02-25

Family

ID=10741021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7507412A Ceased JPH09501927A (ja) 1993-08-25 1994-08-19 金属錯体を含んで成る医薬組成物

Country Status (14)

Country Link
US (1) US5824673A (enExample)
EP (1) EP0714294A1 (enExample)
JP (1) JPH09501927A (enExample)
KR (1) KR100331978B1 (enExample)
AU (1) AU698785B2 (enExample)
CA (1) CA2170253A1 (enExample)
FI (1) FI960849A7 (enExample)
GB (1) GB9317686D0 (enExample)
HU (1) HUT74947A (enExample)
NO (1) NO960754L (enExample)
NZ (1) NZ269596A (enExample)
TW (1) TW282401B (enExample)
WO (1) WO1995005814A1 (enExample)
ZA (1) ZA946262B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044286A1 (ja) * 2003-11-07 2005-05-19 Shetech Co., Ltd. 脳梗塞の予防及び／又は治療のための医薬
JP2005519928A (ja) * 2002-02-04 2005-07-07 ハース，ベルナー Ｃｏ放出能力を有する化合物の投与によって哺乳動物を治療する方法と、ｃｏ放出能力を有する化合物ならびにその医薬組成物

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417182B1 (en) * 1993-08-25 2002-07-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US6265441B1 (en) * 1994-05-11 2001-07-24 Jes Olesen Use of no scavengers, inhibitors of antagonists in the treatment of migraine
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
PL317192A1 (en) * 1994-05-13 1997-03-17 Monsanto Co Methods of using pernitrite decomposition catalyst and their pharmaceutic compositions
US6743771B2 (en) * 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
DE19860289C2 (de) * 1998-12-21 2003-11-13 Schering Ag Neue Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
MXPA01009410A (es) * 1999-03-19 2003-06-06 Anormed Inc Composiciones farmaceuticas que comprenden complejos de metal.
AU6928700A (en) * 1999-08-25 2001-03-19 Clarity Biosciences, Inc. Identifying organisms by detecting intronic nucleic acid or encoded proteins
US7335383B2 (en) * 2001-01-16 2008-02-26 The Regents Of The University Of Michigan Generation of nitric oxide in vivo from nitrite, nitrate or nitrosothiols endogenous in blood
US7128904B2 (en) * 2001-01-16 2006-10-31 The Regents Of The University Of Michigan Material containing metal ion ligand complex producing nitric oxide in contact with blood
WO2002077160A2 (en) * 2001-03-01 2002-10-03 Clarity Biosciences, Inc. Methods of making and uses of compositions that modulate intronic region-encoded protein function
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
CN1318430C (zh) * 2003-04-24 2007-05-30 钟文远 一类稀土配合物及其制备方法和在制备治疗肿瘤药物中的应用
US20060008529A1 (en) * 2004-07-12 2006-01-12 Meyerhoff Mark E Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers
US20060039950A1 (en) * 2004-08-23 2006-02-23 Zhengrong Zhou Multi-functional biocompatible coatings for intravascular devices
US20080241208A1 (en) * 2005-06-30 2008-10-02 Charles Shanley Methods, Compositions and Devices For Promoting Anglogenesis
CN101378792A (zh) * 2005-12-02 2009-03-04 密执安大学评议会 聚合物组合物、涂层和装置及其制备和使用方法
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US20080119002A1 (en) * 2006-11-17 2008-05-22 Charles Grosjean Substrate contact for a MEMS device
US8597563B2 (en) 2008-07-11 2013-12-03 Rohm And Haas Company Recycled thermoplastic composition comprising waste thermoset material and methods of making
DE102010014412A1 (de) 2010-04-08 2012-04-19 Friedrich-Schiller-Universität Jena Verwendung von zweikernigen Eisenkomplexen mit schwefelhaltigen Liganden als pharmakologische Wirkstoffe
DE102010014411A1 (de) 2010-04-08 2011-10-13 Friedrich-Schiller-Universität Jena Kohlenmonoxid und Eisen freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
WO2012138988A2 (en) * 2011-04-07 2012-10-11 The Research Foundation Of The City University Of New York Organometallic anti-cancer complexes
PT2699242T (pt) 2011-04-19 2018-01-22 Alfama Inc Moléculas de libertação de monóxido de carbono e utilizações das mesmas
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
DE102012004132A1 (de) 2012-02-29 2013-08-29 Friedrich-Schiller-Universität Jena Kohlenstoffmonoxid freisetzende Materialien und deren Verwendung
DE102014008537A1 (de) 2014-06-04 2015-12-17 Friedrich-Schiller-Universität Jena Wasserlösliche manganbasierte Kohlenstoffmonoxid freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1482811A (fr) * 1960-01-26 1967-06-02 Australian Nat University Pers Nouveaux complexes métallifères d'agents de coordination homogènes, et leur procédé de préparation
WO1986000905A1 (fr) * 1984-07-24 1986-02-13 Byk Gulden Lomberg Chemische Fabrik Gesellschaft M Compositions de ruthenium a effet inhibiteur de tumeurs
EP0188585A1 (de) * 1984-07-24 1986-07-30 Byk Gulden Lomberg Chemische Fabrik GmbH Tumorhemmend wirkende rutheniumverbindungen
US5157032A (en) * 1985-01-18 1992-10-20 The Trustees Of Columbia University In The City Of New York Mixed ligand complexes and uses thereof as binding agents and probes to DNA
IT1230145B (it) * 1989-05-05 1991-10-14 Boehringer Biochemia Srl Complessi di rutenio (iii) come agenti antineoplastici.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519928A (ja) * 2002-02-04 2005-07-07 ハース，ベルナー Ｃｏ放出能力を有する化合物の投与によって哺乳動物を治療する方法と、ｃｏ放出能力を有する化合物ならびにその医薬組成物
WO2005044286A1 (ja) * 2003-11-07 2005-05-19 Shetech Co., Ltd. 脳梗塞の予防及び／又は治療のための医薬

Also Published As

Publication number Publication date
US5824673A (en) 1998-10-20
NO960754D0 (no) 1996-02-23
FI960849L (fi) 1996-02-23
AU698785B2 (en) 1998-11-05
WO1995005814A1 (en) 1995-03-02
HUT74947A (en) 1997-03-28
GB9317686D0 (en) 1993-10-13
NO960754L (no) 1996-04-23
TW282401B (enExample) 1996-08-01
FI960849A0 (fi) 1996-02-23
FI960849A7 (fi) 1996-02-23
HU9600441D0 (en) 1996-04-29
ZA946262B (en) 1995-03-20
NZ269596A (en) 1997-05-26
KR960703609A (ko) 1996-08-31
EP0714294A1 (en) 1996-06-05
KR100331978B1 (ko) 2002-09-26
CA2170253A1 (en) 1995-03-02
AU7390794A (en) 1995-03-21

Similar Documents

Publication Publication Date Title
JPH09501927A (ja) 金属錯体を含んで成る医薬組成物
US6417182B1 (en) Pharmaceutical compositions comprising metal complexes
TW541316B (en) Prodrugs of thrombin inhibitors
US4927808A (en) γ-L-glutamyl-L-cysteine ethyl ester and pharmaceutical compositions containing the same as an effective ingredient
JP2004500321A (ja) 金属錯体を含む薬学的組成物
ES2618677T3 (es) Ácido beta-fenil-alfa-hidroxil-propiónico sustituido, método de síntesis y su uso
US6284752B1 (en) Pharmaceutical compositions comprising metal complexes
US20100105770A1 (en) Therapeutic delivery of carbon monoxide
US4452812A (en) Organic complex of platinum, its preparation and its use for treating malignant tumors
CN113234116B (zh) 一种雷公藤红素衍生物及其制备方法和医用用途
US20020193363A1 (en) Use of nitric oxide scavengers to modulate inflammation and matrix metalloproteinase activity
CA2191850C (en) Cancerous metastasis inhibitor
CN114177177B (zh) 一种乏氧肿瘤选择性激活前药的制备方法
JPS6043351B2 (ja) 老人医学的薬剤の製法
CN102725298A (zh) 作为组蛋白脱乙酰酶抑制剂的羟基取代的金(iii)卟啉络合物
CN106995368B (zh) 一种非atp竞争性fgfr1抑制剂及其应用
CN105246473B (zh) 用于缺铁症状和缺铁性贫血的治疗和预防的Fe(III)络合化合物
JP2016520538A (ja) 鉄欠乏症および鉄欠乏性貧血の治療および予防のためのＦｅ（ＩＩＩ）錯体
JPS6155911B2 (enExample)
CN116874557B (zh) 2-Trp-AA-四氢咔啉-3-羧酸类化合物及其PAF抑制剂的应用
RU2800042C1 (ru) Спиросоединения в качестве ингибиторов ERK и их применение
CN113024450B (zh) 一种二硫代甲酯钴(iii)配合物及其制备方法和应用
JPS6410515B2 (enExample)
JPS6357519A (ja) 発癌プロモ−タ−抑制剤
JPH0480005B2 (enExample)

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050104

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20050523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050628